Sign In
Buy KKR
$93.40
-2.06 (-2.16%)
At Close: Jun 05, 2026
Final Trades: KKR, Palo Alto, Applied Materials and Uber
01:40pm, Thursday, 24'th Apr 2025
(OPTIMIZED VIDEO SPECIFIC DESCRIPTION)
KKR Q1 Preview: A Solid Business, But Sentiment Needs To Catch Up
01:38pm, Thursday, 24'th Apr 2025
KKR & Co. Inc. is set to report Q1 results on May 1, with low expectations but the potential for a positive surprise, especially after a strong last quarter. The $1.2 billion acquisition of Biotage si
KKR Real Estate Finance Trust Inc. Reports First Quarter 2025 Results
04:15pm, Wednesday, 23'rd Apr 2025
NEW YORK--(BUSINESS WIRE)--KKR Real Estate Finance Trust Inc. (“KREF”) (NYSE: KREF) today reported its first quarter 2025 results, which have been posted to the Investor Relations section of KREF'
KKR Launches $1.2 Billion Takeover Bid For Swedish Life-Sciences Company Biotage
02:52am, Tuesday, 22'nd Apr 2025
The deal values the Swedish company at $1.2 billion, and the Biotage board recommended that shareholders accept the offer.
KKR makes $1.2 billion offer for Sweden's Biotage
02:35am, Tuesday, 22'nd Apr 2025
Sweden's Biotage said on Tuesday that KKR had made a cash offer for the Swedish biotechnology firm, valuing it at around 11.6 billion Swedish crowns ($1.22 billion).
KKR Real Estate Finance Trust Inc. Declares Preferred Stock Dividend
04:30pm, Monday, 21'st Apr 2025
NEW YORK--(BUSINESS WIRE)--KKR Real Estate Finance Trust Inc. (the “Company” or “KREF”) (NYSE: KREF) announced that the Board of Directors has declared a dividend of $0.40625 per each issued a
KKR Real Estate Finance Trust Inc. Announces Time Change for its Conference Call to Discuss First Quarter 2025 Results
09:00am, Friday, 18'th Apr 2025
NEW YORK--(BUSINESS WIRE)--KKR Real Estate Finance Trust Inc. (“KREF”) (NYSE: KREF) announced today that it has changed the time of its first quarter 2025 earnings conference call and webcast. The
FS KKR Capital: Buy The Tariff Tantrum, Secure A 13.7% Yield
10:35am, Wednesday, 16'th Apr 2025
FS KKR Capital's stock is undervalued, trading at a 21% discount to NAV, presenting a compelling buying opportunity despite higher-than-average non-accruals and declining net investment income. The BD
Leading Investor Criticizes 60/40 Portfolio: Why Our Approach Is Better
08:30am, Wednesday, 16'th Apr 2025
The traditional 60-40 strategy has failed to deliver meaningful returns during recent market cycles. We discuss why the 60-40 strategy may be structurally broken going forward. We share an approach th
FS KKR Capital: How Good Is This 15% Yield?
07:15am, Wednesday, 16'th Apr 2025
FS KKR Capital offers a high dividend yield of 15%, with shares trading at an inexpensive valuation, making it an attractive entry point. Despite a 12% decline in net investment income per share, the
KKR nears acquisition of German IT services firm Datagroup, sources say
02:19pm, Tuesday, 15'th Apr 2025
Private equity firm KKR is close to acquiring Frankfurt-listed IT services provider Datagroup , people familiar with the matter told Reuters on Tuesday.
KKR's "White Knight" Strategy in Buying Assets
08:47am, Tuesday, 15'th Apr 2025
Henry McVey, KKR's Head of Global Macro and Asset Allocation joined Wall Street Beat on Bloomberg Open Interest to talk about KKR's activism strategy. -------- More on Bloomberg Television and Markets
CME Group, S&P Group Agree to Sell OSTTRA to KKR in $3.1 Billion Deal
07:48am, Monday, 14'th Apr 2025
CME Group and S&P Global have agreed to sell OSTTRA to investment funds managed by investment firm KKR for an enterprise value of $3.1 billion.
Buyout firm KKR to buy OSTTRA in $3.1 billion deal
07:04am, Monday, 14'th Apr 2025
Private equity firm KKR will buy post-trade services company OSTTRA in a $3.1 billion deal, S&P Global and CME Group announced on Monday.
S&P Global and CME Group to sell OSTTRA to KKR for $3.1 billion
07:00am, Monday, 14'th Apr 2025
NEW YORK , April 14, 2025 /PRNewswire/ -- S&P Global and CME Group today announced the signing of a definitive agreement to sell OSTTRA, a leading provider of post-trade solutions for the global OTC m
